JGC
ANAB icon

J. Goldman & Co’s AnaptysBio ANAB Stock Holding History

J. Goldman & Co’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,205
Closed -$1.18M – 705
2026
Q1 		$1.18M Buy
+21,205
New +$1.14M 0.03% 398

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

J. Goldman & Co's ANAB Position: Q2 2026 in Review

J. Goldman & Co sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 21,205 shares — an estimated $1.18M sold.

J. Goldman & Co first reported a position in ANAB in Q1 2026 and held it in 1 quarter. The position peaked at $1.18M in Q1 2026. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • J. Goldman & Co reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 21,205 AnaptysBio shares in Q2 2026, an estimated $1.18M.
  • J. Goldman & Co first reported a position in AnaptysBio in Q1 2026 and held it in 1 quarter.
  • J. Goldman & Co's AnaptysBio position peaked at $1.18M in Q1 2026.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.